Cargando…

POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS

Detalles Bibliográficos
Autores principales:	BEIRÃO, B., Freitas, M., Francisco, J., Sousa, C., Pereira, P., Prata, C., Castro, R., Morgado, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854947/ http://dx.doi.org/10.1016/j.ekir.2022.01.968

Ejemplares similares

POS-939 EFFICACY OF BNT162b2 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS IN NORTH OF PORTUGAL
por: FRANCISCO, J., et al.
Publicado: (2022)

POS-940 ANTIBODY RESPONSE TO PFIZER BNT162b2 VACCINE IN HEMODIALYSIS PATIENTS: THE PREVIOUS SARS-CoV-2 INFECTION INFLUENCE
por: FREITAS, M., et al.
Publicado: (2022)

POS-923 RESPONSE TO AND OUTCOMES OF THE Pfizer BNT162B2 VACCINE IN HEMODIALYSIS PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY
por: AlMuhaiteeb, A., et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS
por: Yau, K., et al.
Publicado: (2022)

POS-954 COVID-19 IN PATIENTS ON PERITONEAL DIALYSIS
por: MOHD DIN, M.R., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

POS-685 SARS-COV2 INFECTION IN PATIENTS ON PERITONEAL DIALYSIS
por: Bettaieb, A., et al.
Publicado: (2022)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
por: Altermanini, Mohammad, et al.
Publicado: (2023)

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
por: Kaiser, Robert A., et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

POS-703 COVID-19 IN PATIENTS ON PERITONEAL DIALYSIS : A MONOCENTRIC EXPERIENCE
por: OUNI, A., et al.
Publicado: (2022)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients—A prospective observational study
por: Al‐Muhaiteeb, Abdullah, et al.
Publicado: (2022)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Severe hyponatraemia with cerebral oedema after Pfizer BNT162b2 mRNA vaccination against COVID-19
por: Dharma, J.F.M., et al.
Publicado: (2023)

Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
por: Yau, Kevin, et al.
Publicado: (2022)

Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine
por: Piotrowska, Magdalena, et al.
Publicado: (2022)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
por: Kim, Eun-Ju, et al.
Publicado: (2023)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
por: Lim, Xin Rong, et al.
Publicado: (2023)

POS-666 COVID-19 IN ESRD PATIENTS WITH PERITONEAL DIALYSIS: A SYSTEMATIC REVIEW
por: Nopsopon, T., et al.
Publicado: (2021)

POS-646 CHALLENGING MANAGEMENTOF A CRITICAL COVID-19 PATIENT WITH PERITONEAL DIALYSIS
por: AJIMI, K., et al.
Publicado: (2021)

POS-010 NEONATAL COVID-19 WITH ACUTE KIDNEY INJURY: EXPERIENCE WITH PERITONEAL DIALYSIS
por: Kumthekar, G., et al.
Publicado: (2022)

Humoral immunity against Covid-19 six months after the Pfizer BNT162b2 vaccine in hemodialysis patients: data from five dialysis units. Is there a protective role for hemodiafiltration in the Covid-19 pandemic?
por: Chuva, Teresa, et al.
Publicado: (2022)

POS-958 CORONAVIRUS-DISEASE 2019 (COVID-19) IN CHRONIC PERITONEAL DIALYSIS POPULATION: CHARACTERISTICS AND OUTCOME
por: RADHA KRISHNA, J., et al.
Publicado: (2022)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a20cr7qjho70g3q7a1t0ss34i8